Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

Trial ID or NCT#

NCT03859700

Status

not recruiting iconNOT RECRUITING

Purpose

Open-label, follow-up study for subjects who completed the EPITOPE study.

Official Title

EPITOPE Open-label Extension Study to Evaluate the Long-term Clinical Benefit and Safety of DBV712 in Peanut-Allergic Children

Eligibility Criteria

Ages Eligible for Study: 2 Years to 5 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - completion of the EPITOPE study
Exclusion Criteria:
  1. - Generalized dermatologic disease (for example, active atopic dermatitis, uncontrolled generalized active eczema, ichthyosis vulgaris) extending widely on the skin and especially on the back or arms with no intact zones to apply the Viaskin patches. - Diagnosis of asthma that evolved to severe, unstable or uncontrolled asthma
View All Criteria
Show Less

Investigator(s)

Sayantani Sindher
Allergist, Immunologist
Clinical Associate Professor, Medicine Clinical Associate Professor, Pediatrics - Allergy and Clinical Immunology

View on ClinicalTrials.gov